Stocktoria
Cardiff Oncology, Inc. CRDF
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2004-07-27
Cardiff Oncology, Inc. statistics & valuation
Market cap$85.5M
P / B1.9×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -8256.3% | -7123.1% | -9305.7% | -10337.3% | -8037.6% |
| Net margin | -7732.0% | -6651.7% | -8492.0% | -10026.9% | -7880.5% |
| FCF margin | -6402.5% | -5530.5% | -6448.6% | -9022.3% | -6474.9% |
| Return on assets | -74.1% | -46.7% | -50.8% | -33.3% | -18.9% |
| Return on equity | -101.0% | -54.8% | -59.4% | -36.4% | -20.1% |
| Current ratio | 3.67 | 7.08 | 7.41 | 14.25 | 22.28 |
| Revenue growth | -13.2% | 40.0% | 26.4% | 7.5% | -1.9% |
Source: SEC EDGAR filings · CIK 0001213037 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.